Navigation Links
Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
Date:7/31/2009

CARLSBAD, Calif., July 31 /PRNewswire/ -- Excaliard Pharmaceuticals, a late stage preclinical company developing targeted therapeutics for the treatment of skin scarring and fibrotic disorders, is pleased to announce that Jay Birnbaum, Ph.D. has joined the Board of Directors as an Independent Board Member.

Dr. Jay Birnbaum is a dermatology consultant specializing in ethical and OTC drugs, medical devices, and cosmeceuticals. His 35 years of industry experience span the areas of discovery research, formulations, clinical R&D, regulatory and marketing, and he has been involved in the development and commercialization of numerous drug and consumer products and brands. Dr. Birnbaum is a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals, a company developing products in aesthetic dermatology. Prior to starting his own consulting company in 1999, he was with Novartis/Sandoz Pharmaceuticals Corporation, serving most recently as Vice President, Global Project Management, with responsibilities for strategic planning and development of the company's dermatology portfolio. Prior to that, Dr. Birnbaum held various management positions at the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth).

Dr. Birnbaum has broad relationships in industry and academia, and has published extensively on his work in drug development. His professional affiliations include the American Academy of Dermatology, Society of Investigative Dermatology, European Academy of Dermatology and Venereology, American Society for Dermatologic Surgery, and International Society of Dermatology. He is a member of the board of directors of Oculus Innovative Sciences, Inc. and is on the Science Advisory Boards of Evolva, NanoBio Corp, NexMed, Inc., Topica Pharmaceuticals, and Transport Pharmaceuticals.

He received a B.S. degree from Trinity College and a Ph.D in Pharmacology from the University of Wisconsin.

Excaliard Pharmaceuticals, Inc,(R) is delighted to have an individual with Jay's technical and business experience join the Board of Directors and looks forward to his many contributions.


'/>"/>
SOURCE Excaliard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases
2. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
3. ISTA Pharmaceuticals Announces Conference Call and Webcast of Second Quarter 2009 Financial Results
4. Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
5. Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August
6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009
7. Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
9. Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
10. Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research
11. Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: